Screener
Nuvation Bio NUVB Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| For the Six Months Ended June 30, | 2026 | 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(57,443) | $(112,243) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 19,493 | 19,885 |
| Depreciation and amortization | 1,072 | 666 |
| Non-cash lease expense | (120) | 335 |
| Non-cash interest on revenue interest financing agreement | 10,176 | 266 |
| Amortization of debt issuance costs | 671 | 18 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's stock-based comp?
- Nuvation Bio (NUVB) reported stock-based comp of $10.46M in Q2 2026.
- How has Nuvation Bio's stock-based comp changed year-over-year?
- Nuvation Bio's stock-based comp decreased by 13.1% year-over-year, from $12.03M to $10.46M.
- What is the long-term trend for Nuvation Bio's stock-based comp?
- Over 4 years (2021 to 2025), Nuvation Bio's stock-based comp has grown at a 40.3% compound annual growth rate (CAGR), from $9.27M to $35.89M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Nuvation Bio's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude